STOCK TITAN

Exyn Technologies (EXYN) 424B Filings

EXYN NASDAQ

Here are the 424B prospectus supplements from Exyn Technologies, Inc. (EXYN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow EXYN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXYN filings page.

Rhea-AI Summary

Exyn Technologies, Inc. (EXYN) filed a prospectus supplement for the resale by existing selling stockholders of up to 3,658,564 shares of common stock and 189,753 warrants. Exyn will not receive proceeds from these resales. Its common stock and warrants trade on Nasdaq under “EXYN” and “EXYNW,” last closing at $2.02 and $0.66, respectively, on August 19, 2026.

Exyn’s June 30, 2026 balance sheet shows total assets of $11.8 million, including $7.8 million in cash and cash equivalents, and total liabilities of $6.2 million, for positive stockholders’ equity of $5.6 million. For the six months ended June 30, 2026, revenue was $2.1 million with a net loss of $10.1 million. The company completed an IPO on May 18, 2026, raising gross proceeds of approximately $19.4 million, and used a portion to repay prior debt. Exyn discloses recurring losses, negative operating cash flows and states that its current cash is expected to be insufficient for the next 12 months, indicating substantial doubt about its ability to continue as a going concern absent additional financing.

Rhea-AI Summary

Exyn Technologies, Inc. files a prospectus supplement registering up to 3,658,564 shares of Common Stock and up to 189,753 warrants for resale by selling stockholders; the company will receive no proceeds from those resales.

The supplement incorporates Exyn’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $1,102,166, a net loss of $3,238,785 for the quarter, SAFEs valued at $6,917,000, and shares outstanding of 7,953,957 as of June 29, 2026. The Form 10-Q discloses substantial doubt about the company’s ability to continue as a going concern and the company states it is pursuing additional funding.